From this week's @JAMAOnc: "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors". This is largest evaluation of this topic, providing details of how , when, from what regimens, & how often fatalities from immunotherapy occur. Worth knowing. ja.ma/2xkpTBw pic.twitter.com/wEgEr1I7Jf

We usually only hear and read about the bright side of #cancer immunotherapy. Here's the dark side: jamanetwork.com/journals/jamao… @JAMAOnc @VUMChealth @VUmedicine pic.twitter.com/XAFQGMzSyN

This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment. Learn more: ja.ma/2rkiVto #ASH18 pic.twitter.com/npZxrffara

Nice review in @JAMAOnc details incidence and timing of #immunotherapy-related fatalities medicalxpress.com/news/2018-09-i… jamanetwork.com/journals/jamao… $BMY $MRK $RHHBY $AZN $PFE pic.twitter.com/iLSpzjlfs5

Great work from ⁦@VUMChealth⁩ looking ⁦@WHO⁩ pharmacovigilance data to study fatal immune-related AEs ⁦⁦@CardioOncology⁩, rare but important to be aware.

At #ASH18? Visit Booth 2805 today before 5 p.m. to get a copy of "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis" ja.ma/2FGP5t1 pic.twitter.com/7nDzKgv4Ry

Fatal toxicity with immune checkpoint inhibitors is not common but does occur; vigilance remains key; most occur in the early period (median 40 days with single agent; 14 days with combination) ja.ma/2xhs3lo #bladdercancer #immunotherapy @B_C_A_N

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis #ImmunoOnc

Metanálise sobre Toxicidades Fatais relacionadas aos Inibidores de Checkpoint no @JAMAOnc: evento raro, mas de grande relevância jamanetwork.com/journals/jamao… #Immunotherapy @FabioSchutz78 @camillayamada @RoselyYamamura @rcarvalhoonco @lvsantosmd Veja mais em mocbrasil.com pic.twitter.com/Si7HiUoE45

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis. A broad range of regimen-specific toxic effects caused fatalities in 0.3% to 1.3% of treated patients. JAMA

Mechanisms of fatal Immune checkpoint inhibitor (ICI) events: large study shows early onset of death with varied causes. Risk varies by therapeutic regimen. Rare events. Important clinical knowledge. #mmsm ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩

Important and thorough analysis on the fatalities attributed to I/O treatments and combinations. Almost half of Rx fatalities occur within 3 months - has anyone found some combination of host genetics and immune status to identify pts at greatest risk?